Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 15/20 | 0.49 |
| ▸ | PGR | P06401 | 4/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3180495 | 0.83 | AR (0.41) | ARPGRNR3C2NR3C1KDM4E | |
| SCHEMBL1196089 | 0.80 | AR (0.43) | ARKDM4EUSP2ALDH1A1 | |
| SCHEMBL20567319 | 0.80 | AR (0.42) | ARKDM4EUSP2ALDH1A1 | |
| SCHEMBL14129988 | 0.79 | ALDH1A1 (0.43) | ARALDH1A1 | |
| SCHEMBL3976812 | 0.78 | AR (0.51) | ARPGRNR3C2 | |
| SCHEMBL29863815 | 0.78 | AR (0.51) | ARPGRNR3C2ALDH1A1 | |
| SCHEMBL13106347 | 0.78 | AR (0.51) | ARPGRNR3C2ALDH1A1 | |
| SCHEMBL2965465 | 0.77 | ALDH1A1 (0.42) | ARPGRKDM4EALDH1A1 | |
| SCHEMBL2428317 | 0.77 | GRM6 (0.41) | ARPGRKDM4EUSP2ALDH1A1 | |
| SCHEMBL1642132 | 0.75 | AR (0.49) | ARPGRNR3C2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| US-20230146829-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIV TENNESSEE RES FOUND (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146829-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIV TENNESSEE RES FOUND (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230115515-A1 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2023-04-13 | — | — | US | disclosed |
| CN-115701991-A | Pyrazolylpropionamide compounds and their use for treating prostate cancer | 田纳西大学研究基金会 | 2023-02-14 | — | — | CN | disclosed |
| EP-4125846-A1 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | University of Tennessee Research Foundation (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4110327-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | University of Tennessee Research Foundation (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-115484947-A | Selective Androgen Receptor Degrader (SARD) ligands and methods of use thereof | 田纳西大学研究基金会 | 2022-12-16 | — | — | CN | disclosed |
| WO-2021202936-A9 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021202936-A1 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2005077925-A1 | SULFONYLPYRROLODINE MODULATORS OF ANDROGEN RECEPTOR FUCTION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050187267-A1 | Sulfonylpyrrolidine modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-25 | — | — | US | disclosed |
| CN-1589271-A | Fused heterocyclic succinimide compounds and analogs thereof as modulators of nuclear hormone receptor function | BRISTOL MYERS SQUIBB CO (US) | 2005-03-02 | — | — | CN | disclosed |
| EP-1506178-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1458723-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristols-Myers Squibb Company (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-29 | — | — | US | disclosed |
| WO-2003096980-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003062241-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | AR 1/4885PGR 114/4885NR3C2 22/4885 |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | AR 33/4885PGR 68/4885NR3C2 41/4885 |
| US-20050187267-A1 | Sulfonylpyrrolidine modulators of androgen receptor function and method | NR3C2, AR, NR4A3 | AR 2/4885PGR 119/4885NR3C2 1/4885 |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | AR 1/4885PGR 120/4885NR3C2 21/4885 |
| US-20230146829-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, FSHR | AR 1/4885PGR 103/4885NR3C2 517/4885 |
| US-20230115515-A1 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | AR, KLK3, ACP3 | AR 1/4885PGR 286/4885NR3C2 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.